DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20210556

A multivariate comparative clinical pharmacotherapeutic efficacy and chronopharmacovigilance assessment study of ofloxacin, one of the commonplace, TGFβ1 inducing and telomerase impairing fluoroquinolones, in treating acute gastroenteritis, chronic obstructive pulmonary disease, new drug-sensitive tuberculosis, recurrent mixed cutaneous infections, and post-surgical refractory wound infections, among the global patients, with heterogenous pharmacogeographic and pharmacogenomic constitution

Moumita Hazra

Abstract


Background: Ofloxacin has an inhibitory effect on DNA gyrase, DNA topoisomerase IV and IL-1α, IL-6, IL-8, TNFa; and a superinducing effect on IL-2. Ofloxacin has profound bactericidal, anti-tubercular, anti-leprotic, anti-viral including anti-coronavirus, anti-fungal, anti-protozoal, comedolytic, anti-comedogenic, anti-inflammatory, immunomodulatory, and anti-malignant: pro-apoptotic and anti-proliferative potential, including TGFb1 targeted G2 phase cell cycle arrest and telomerase activity impairment. Objectives of the study were a comparative clinical pharmacotherapeutic efficacy and chronopharmacovigilance assessment study, of ofloxacin, one of the commonplace TGFb1 inducing and telomerase impairing fluoroquinolones, in treating heterogenous global patients, suffering from different diseases.

Methods: A prospective, multivariate study of 100 patients, allotted into group A (acute gastroenteritis) =20, group B (chronic obstructive pulmonary disease) =20, group C (new drug-sensitive tuberculosis) =20, group D (recurrent mixed cutaneous infections) =20, and group E (post-surgical refractory wound infections) =20, was prescribed ofloxacin 200-400 mg twice daily, according to required prescribed regimens. A comparative pharmacotherapeutic efficacy assessment was made from the complete recovery time-periods, including the residual recovery time-periods. The chronopharmacovigilance assessment was made by adverse effects occurrence monitoring during treatment period or follow-up, with an Adverse Event Case Report Form. 

Results: The residual recovery time-periods, in group A=0 days, group B=2 days, group E=3 days, group D=3 days, and group C=7 days. Adverse effects were not statistically significant, with a predictable chronopharmacovigilance illustration.

Conclusions: The pharmacotherapeutic efficacy of ofloxacin was more for treating group A, followed by group B, followed by group E and group D, and finally followed by group C. Ofloxacin was safe, without any pharmacogenomic or pharmacogeographic heterogeneity related fluctuation.


Keywords


Ofloxacin, TGF1, Telomerase, Pharmacotherapeutic efficacy, Chronopharmacovigilance, Indication spectrum

Full Text:

PDF

References


Hazra M. A rational pharmacotherapeutic study of comparative safety among topical anti anti-acne 1% nadifloxacin monotherapy, 0.1% adapalene monotherapy, 0.025% tretinoin monotherapy, 1% nadifloxacin and 0.1% adapalene combination therapy and 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne vulgaris, in tertiary care hospitals. Int J Basic Clin Pharmacol. 2019;8(9):1959-65.

Hazra M. A rational pharmacotherapeutic study in pharmacovigilance: a comparative assessment of safety between topical 1% nadifloxacin and 0.1% adapalene combination therapy and topical 1% nadifloxacin and 0.025% tretinoin combination therapy, in mild to moderate acne, in tertiary care hospitals, in India. J Evid Based Med Healthc. 2019;6(35):2366-71.

Hazra M, Geetha M, Somashekhar HS, Murugesh SB. A comparative study on the efficacy of topical 1% nadifloxacin and 0.1% adapalene combination therapy with 1% clindamycin and 0.1% adapalene combination therapy, in mild to moderate acne, in a tertiary care hospital. Indian J Pharmacol. 2014;46(7-1):S73.

Brar RK, Jyoti U, Patil RK, Patil HC. Fluoroquinolone antibiotics: an overview. Adesh Univ J Med Sci Res. 2020;2(1):26-30.

Assar S, Nosratabadi R, Azad HK, Masoumi J, Mohamadi M, Hassanshahi G. A review of immunomodulatory effects of fluoroquinolones. Immunol Invest. 2020;1-20.

Garcia-Prats AJ, Draper HR, Thee S, Dooley KE, McIlleron HM, Seddon JA, et al. Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis. Antimicrob Agents Chemother. 2015;59(10):6073-9.

World Health Organization. Fact sheet: Differences among fluoroquinolones in the treatment of MDR-TB. Geneva, Switzerland: World Health Organisation Archives; 2020. Available at https://www.archives. who.int. Accessed on 01 February, 2021.

Yadav V, Talwar P. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: an underestimated truth. Biomed Pharmacother. 2019;111:934-46.

Idowu T, Schweizer F. Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics. 2017;6(4):26.

Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, et al. Antibiotics for cancer treatment: a double-edged sword. J Cancer. 2020;11(17):5135-49.

Mohammed HHH, Abuo-Rahma GEAA, Abbas SH, Abdelhafez ESMN. Current trends and future directions of fluoroquinolones. Curr Med Chem. 2019;26(17):3132-49.

Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51(7):741-2.

Pradhan S, Prajna NV. Topical fluoroquinolones: current perspectives. DJO. 2015;25:267-71.

Vergalli J, Atzori A, Pajovic J, Dumont E, Malloci G, Masi M, et al. The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux. Commun Biol. 2020;3(1):198.

Kasabri V, Arabiyat S, Al-Hiari Y, Zalloum H, Almaliti J, Telfah A, et al. Fluoroquinolones as a potentially novel class of antidiabesity and antiproliferative compounds: synthesis and docking studies. Can J Chem. 2020;98(10):635-45.